['rett syndrome']
['glatiramer acetate (copaxone®)']

        Inclusion Criteria:

          1. Females, age 6-15 years (inclusive).

          2. Patients whose parents or legal custodians have provided written informed consent to
             participate in the study.

          3. A diagnosis of RTT (classical or variant), defined according to the internationally
             agreed 2010 RetSearch criteria [4].

          4. Evidence of a genetically defined pathological change in the MECP2 gene (point
             mutation or deletion)

          5. Patients with known epileptiform activity as recorded on EEG.

          6. Blood pressure and heart rate within normal limits (blood pressure: systolic 90-140
             mmHg; diastolic 50-90 mmHg, heart rate 40-120 beats per minute

          7. An electrocardiogram (ECG) which, according to the Investigator's judgment does not
             contraindicate participation in the study.

          8. No clinically significant abnormalities in haematology, blood chemistry lab tests at
             screening.

          9. Parents must be able to understand the requirements of the study and must be willing
             to comply with the requirements of the study

        Exclusion Criteria:

          1. Any medical problem or chronic illness beyond those known to be associated with Rett
             Syndrome which, in the investigator's judgment, contraindicates administration of the
             study medication.

          2. Severe respiratory dysfunction (defined as tracheostomy and/or chronic oxygen therapy
             at least 4 hours a day and/or repeated aspiration pneumonia - at least 4 in the last
             year).

          3. Intractable seizures that started during the last 6 months prior to beginning of the
             study.

          4. Known hypersensitivity to glatiramer or mannitol.

          5. Participation in another clinical study.

          6. Parents of a patient who are unable to communicate well with the investigator and
             staff and comply with study procedures and follow-up

          7. Parents of a patient who are unwilling to sign consent form.
      